Work

A Randomized Phase 3 Study Comparing First-Line Docetaxel/Prednisone (Dp) to Dp Plus Custirsen in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Year: 2014

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu336.3

Authors: K.N. Chi, C. Higano, J. Reeves, S. Feyerabend, G. Gravis, J. Ferrero, C. Jacobs, O. Barnett-Griness, A. Pande, J.S. de Bono

Institutions: BC Cancer Agency, University of Washington, Fred Hutch Cancer Center, Florida Cancer Specialists & Research Institute, Institut Paoli-Calmettes, Centre Antoine Lacassagne, OncoGenex Pharmaceuticals (United States), Teva Pharmaceuticals (Israel), Teva Pharmaceuticals (United States), Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2247731044

FWCI: 1.606

Cites:

Cited by: 6

Related to: 10